Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...
Alterity Therapeutics (ATHE) announced that the last patient in the ATH434-202 Phase 2 trial has completed the study. The ATH434-202 is an open ...
20h
The mammalian immune system is an evolutionary wonder. It's capable of recognizing and destroying cancer cells, and it can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback